The growing awareness of the need for pharma ceutical products to treat rare diseases led to the enactment of rare diseases legislation in the United States (Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat. Rev. Drug Discov. 9, 510-522 (2010)) 1 , the European Union 2 and Japan 3 (see also Further information). The European Medicines Agency (EMA) has been engaged in collaborations with the US Food and Drug Administration (FDA)'s Office of Orphan Products Development (OOPD) since 2000 and with the Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) Orphan Drug Designation Service since 2010. Identifying areas of simi larity among these programmes has led to activities aimed at reducing redundancies and the administrative load for sponsors inter ested in submitting applications for orphan drug designation in each region, allowing for transparency and an increased sponsor under standing of each agency's processes and incen tives (TABLE 1) . It is hoped that there will be an increase in awareness of the benefits of par allel submission both at the orphan designa tion stage and postdesignation, where input through protocol assistance (scientific advice) and paediatric input are subject to incentives. The reduction in regulatory consultation times and improved efficiencies in drug develop ment due to these collaborative efforts should translate into accelerated timelines for the approval of successful orphan drugs.
EMA-FDA collaboration
In 2007, a joint application form for orphan drug submissions in the United States and the European Union was introduced, reducing the sponsor's administrative burden and encourag ing parallel submissions to both agencies. The agencies have worked together to understand areas of similarity at the time of submission for an orphan drug designation, enhancing the understanding of key assessment criteria, which are similar in both systems. Definition of an orphan condition. The spon sor often plans for development of a drug for a specific therapeutic indication that falls within an orphan disease or condition. Therefore, often the overall orphan disease or condition may be broader than the therapeutic indication that the sponsor plans to study for marketing approval. Although there is some variance between the interpretations by both agen cies 4, 5 , there has been an effort by both parties to understand the other's approach to setting the boundaries of a rare disease or condition at the time of designation. They also aimed to produce less variance in the review approach for the same product when a sponsor seeks a designation at the EMA and FDA. Through this type of collaboration, the postdesignation clinical development may be more focused, thereby increasing efficiencies in development and the probability of success. The agencies also consult each other regarding changes in classifications or definitions of orphan condi tions that have occurred as a consequence of advances in science.
Medical plausibility and scientific rationale. Both agencies require sponsors to submit data to support the hypothesis that the product has a mode of action that has sound pharmacologi cal principles regarding the product's potential use in the condition 6 . Preliminary surveys conducted independently by both agencies show that ~30% of submissions that have demonstrated acceptable medical plausibility use preclinical in vivo data, and the remainder generally have promising preliminary clinical data with the product in patients with the con dition (FIG. 1a) . Only a very small percentage of acceptable medical plausibility sections have preclinical data limited to in vitro data (2% for both the FDA and EMA) (FIG. 1b) . This scien tific rationale prerequisite has been identified as necessary in establishing an orphan designa tion in both systems, and similar datasets can be used in a sponsor's submission.
Prevalence. The US legislation defines a 'rare disease or condition' as a disease or a condi tion that affects fewer than 200,000 people in the United States. In the European Union, the orphan regulation establishes that the prevalence has to be based on epidemiological data from the European Economic Area (EEA; consisting of the 28 EU Member States in addi tion to Norway, Liechtenstein and Iceland) and must not be more than 5 in 10,000 people. In the United States, the number corresponds to a higher prevalence rate (around 7 in 10,000) than in Europe, which means that certain con ditions may obtain an orphan designation in the United States but do not qualify in Europe.
Procedural aspects. Text used to describe the rare disease or condition and the medical plausibility and scientific rationale will not vary much in view of the similarity of the require ments, making the only different task the prevalence calculation. In the European Union, once a submission is validated, a start date is given and the procedure lasts a maximum of 90 days with no clockstop period permitted. There is no time limit specified in the law or in FDA regulation within which the FDA must respond to a submission request, although the FDA OOPD works to provide sponsors with a timely response.
In the European Union, there is the addi tional requirement of conducting a search for other pharmaceutical medicinal products authorized for use in the orphan condition and the need to establish, where necessary, the basis for the assumption of significant benefit. Significant benefit is defined either as a clini cally relevant advantage or a major contribu tion to patient care that the product may give. Additionally, the EMA requests that spon sors explain the current status of the product development programme as well as regulatory considerations associated with orphan drug designation.
Both agencies have worked to enhance the transparency of the administrative require ments on their websites. In 2011, both agencies agreed that it was acceptable to receive annual reports using the template provided through the EMA and available on the EMA orphan web section, reducing the need for duplica tion and instead focusing on the information, which was relevant to both agencies.
Topics also under consideration for fur ther consultation are the data requirements for the principles of clinical superiority and major contribution to patient care. The FDA and EMA have established a parallel scientific advice procedure, which includes products that have obtained an orphan designation. Parallel scientific advice offers the possibility of resolving questions about clinical data needs, thereby offering the potential of making clinical development programmes more effi cient and reducing times from submission to approval.
Joint annual workshops were established in 2011 at which both agencies present the basis of their orphan designation systems and con siderations for postdesignation processes.
It has been noted that currently ~50% of submissions to the EMA are done in parallel with the FDA, with ~30-40% of applicants using the joint FDA-EMA application form. Although the review processes are done inde pendently, most sponsors obtain their respec tive orphan designation in both regions within a maximum of 6 months of each other.
EMA collaboration with the MHLW/PMDA The EMA's collaboration with the MHLW/ PMDA began in late 2010. Two of the aims of this collaboration are the creation of greater mutual awareness of the submission processes for orphan medicine designations and the development of a system of exchange regarding the outcomes of orphan designations.
Due to the administrative differences between the EMA and the MHLW/PMDA, a common designation application form was not considered feasible. All submissions to Japanese authorities have to be submitted in Japanese. The EMA and the MHLW/PMDA have worked together to establish greater clarity regarding each other's processes in the hope of encourag ing parallel submissions and facilitating access to mutual incentive programs for orphan designated products. An English website for the MHLW was developed, and the EMA Orphan Designation website has some links to the MHLW' s website. The MHLW also provides consultations that help sponsors to understand the regulatory process and administrative needs regarding submission requirements.
The MHLW is primarily involved in admin istrative steps regarding orphan designation, and assessment work is performed primarily by the PMDA. The Pharmaceutical Affairs and Food Sanitation Council (PAFSC) discuss the assessment provided by the PMDA. The PAFSC makes the recommendation to the MHLW on whether to grant a designation, and the MHLW officially grants it. There is no time limit for the assessment process and it is similar to the FDA assessment process. One similarity between the Japanese and the European systems is the use of a committee of independent experts to make a recommendation for granting a designation.
Definition of an orphan condition. The MHLW/PMDA require similar considerations to those requested by the EMA when describ ing the orphan condition in an application 3 . • Financial subsidies for up to 50% of expenses for clinical and non-clinical research • Subsidies through the NIBIO to reduce the financial burden of product development • User fee waivers, 15% tax credits, up to 20% corporate tax reduction and a 30% reduction in marketing application fees
Marketing exclusivity
• 7-year marketing exclusivity is granted to a product that, after receiving an orphan designation, goes on to receive a marketing approval as an orphan drug, meaning that the FDA cannot approve another (competing) marketing application for the 'same' drug treating the 'same' orphan diseases or conditions.
• The 10-year market exclusivity protects against a similar drug being authorized for the same therapeutic indication • Three derogations from this rule exist: first, sponsor's consent; second, lack of supply; and third, if a new product (although similar) could be demonstrated to be 'clinically superior', that is, 'safer, more effective or otherwise clinically superior' than the product already on the market
• Extension of the re-examination period to 10 years at marketing authorisation Scientific advice (protocol assistance)
• Access to free scientific guidance at the FDA • Guidance by the relevant review division at the FDA on the regulatory requirements for quality, non-clinical development and the design of the clinical trials to demonstrate the efficacy and safety of the drug
• Access to free-of-charge protocol assistance at the EMA • Guidance on the regulatory requirements regarding quality, non-clinical development and the design of the clinical trials necessary to fulfil the regulatory requirements for the demonstration of efficacy and safety of the drug
• A 30% fee reduction for protocol assistance • Guidance is given on the regulatory requirements regarding quality and non-clinical development, as well as on the design of the clinical trials necessary to fulfil the regulatory requirements for marketing authorization
Grants for research programmes
• The FDA Orphan Products Grant Program offers funding for clinical studies (investigating safety and/or effectiveness) that will result in or substantially contribute to market approval • The National Institutes of Health (NIH) also has a grants mechanism for rare diseases
• The European Commission supports rare disease research through its framework programmes and the call for proposals in the rare disease area usually includes Europe-wide studies of the natural history of rare disease, pathophysiology and the development of preventive, diagnostic and therapeutic interventions • Member states offer a variety of grants (see REF. 7) • Support measures include grants in aid for clinical and non-clinical research programs, price-control policies negotiated by Japanese National Health Insurance and pharmaceutical companies, and medical expense reimbursement for 56 diseases • NIBIO and AMED offer grant programmes to small and medium-sized enterprises and researchers who are developing products for rare diseases Applicants may consider submitting similar information used in a European submission when submitting in Japan. This will benefit postdesignation considerations regarding product development and scientific advice, which is conducted by the PMDA, by provid ing a better understanding of how an orphan condition is defined in both Europe and Japan.
Medical plausibility. Some of the evidence of medical plausibility used in a European submis sion may also be used in a Japanese submission. There is a difference between the two systems concerning the level of evidence required to support the medical plausibility. In Europe, both preclinical data in a valid in vivo model and/or preliminary clinical data are accepted as the basis for supporting the hypothesis that the product holds promise for the condition. In Japan, the MHLW/PMDA require a higher level of evidence for the purpose of assessment of medical plausibility, as a sponsor should present data from clinical studies to support medical plausibility.
Prevalence. The prevalence threshold in Japan is different to the one required in Europe, and it is similar to the FDA's in that it is based on a number of patients rather than a percentage.
The number of patients who may require an orphan drug should be less than 50,000 in Japan, and this calculation must be based on epidemiological data from Japan. Additionally, the sources that are acceptable to the MHLW/ PMDA should be discussed with them at the consultation meeting.
The MHLW/PMDA request applicants to demonstrate that there are high medical needs satisfying one of the following criteria: there is no appropriate alternative drug or treatment, and high efficacy or safety is expected com pared with existing products. So, the scientific submission section in Japan has similarities with a European submission. Such similarities in format and criteria could help to reduce the administrative burden for sponsors considering submission to the two systems.
Japan participated in the latest Joint Orphan Workshop with the FDA and the EMA, which was held in London, UK, in March 2014. These meetings allowed sponsors to discuss regula tory considerations in Japan and Europe as well as incentive programmes, with the hope that this will help to create greater efficiencies in postdesignation product development and marketing authorisation submissions. The EMA has had discussions with the PMDA regarding similarities and differences in the scientific advice process regarding products that have obtained an orphan designation.
Conclusion
Many countries have introduced a combina tion of regulations and policies for orphan drugs in the last two decades. Through par allel submissions and greater transparency of incentive programmes, having early and frequent interactions with regulators, it is hoped that a more global approach to the development of orphan medicines can be fos tered, ultimately leading to greater benefits for patients with rare diseases. 
